Anti‐CD44 and EGFR Dual‐Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple‐Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and <i>In Vitro</i> Characterization

Abstract

Overall, the finding of this investigation suggested that SLNs/DOX/Dexa/CD44/EGFR could be a promising new enhanced anticancer delivery system and deserved further preclinical consideration.